Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
PHASE2CompletedINTERVENTIONAL
Enrollment
78
Participants
Timeline
Start Date
March 31, 2002
Primary Completion Date
November 30, 2006
Conditions
Adult Primary Cholangiocellular CarcinomaAdult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerCholangiocarcinoma of the Extrahepatic Bile DuctCholangiocarcinoma of the GallbladderLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver CancerRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder Cancer
Interventions
DRUG
erlotinib hydrochloride
Given orally
OTHER
laboratory biomarker analysis
Correlative studies
Trial Locations (1)
55905
Mayo Clinic, Rochester
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00033462 - Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer | Biotech Hunter | Biotech Hunter